Get the Stockscreener App
7.50
3.78%
-0.295
After Hours:
7.52
0.02
+0.27%
Cvrx Inc stock is traded at $7.50, with a volume of 160.49K.
It is down -3.78% in the last 24 hours and down -16.76% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$7.795
Open:
$7.91
24h Volume:
160.49K
Relative Volume:
0.52
Market Cap:
$197.34M
Revenue:
$56.65M
Net Income/Loss:
$-53.31M
P/E Ratio:
-3.6689
EPS:
-2.0442
Net Cash Flow:
$-40.75M
1W Performance:
+0.27%
1M Performance:
-16.76%
6M Performance:
-23.39%
1Y Performance:
-3.72%
1-Day Range:
$7.40
$7.92
1-Week Range:
$6.52
$8.1402
52-Week Range:
$4.2993
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
7.50 | 205.10M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx enrolls first patient in study of Barostim therapy for heart failure - MassDevice
CVRx enrolls first patient in 2,500-patient heart failure trial By Investing.com - Investing.com Australia
CVRx launches landmark BENEFIT-HF trial for cardiac device research - Traders Union
A 2,500-patient heart failure study begins with device access at stake - Stock Titan
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population - Yahoo Finance UK
CVRx reports Barostim therapy boosts quality of life for heart failure patients - Traders Union
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Discipline and Rules-Based Execution in CVRX Response - Stock Traders Daily
Methodist University Hospital completes first Barostim implant with CVRx collaboration - Traders Union
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026 - GlobeNewswire
CVRx will post first-quarter results after the bell on May 11 - Stock Titan
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026 - Traders Union
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
CVRx nominates Michael Dale to board of directors By Investing.com - Investing.com India
CVRx nominates Michael Dale to board of directors - Investing.com
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms - Traders Union
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors - marketscreener.com
Former Abbott structural heart leader Michael Dale lands CVRx board nomination - Stock Titan
CVRx (CVRX) details 2026 virtual meeting, board nominees and pay - Stock Titan
Behavioral Patterns of CVRX and Institutional Flows - Stock Traders Daily
CVRX Should I Buy - Intellectia AI
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026 - Traders Union
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
CVRX Maintained by Canaccord Genuity -- Price Target Steady at $10 - GuruFocus
CVRx (NASDAQ:CVRX) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
CVRx Price Target Maintained With a $10.00/Share by Canaccord Genuity - Moomoo
Lake Street Remains a Buy on CVRx (CVRX) - The Globe and Mail
A Quick Look at Today's Ratings for CVRx Inc(CVRX.US), With a Forecast Between $10 to $14 - 富途牛牛
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
William Blair reiterates CVRx stock rating on strong Q1 results By Investing.com - Investing.com Australia
William Blair reiterates CVRx stock rating on strong Q1 results - Investing.com
CVRx Reports 20% Revenue Growth and Improved Medicare Approval Rates in Preliminary Q1 2026 Results - Minichart
CVRx expects robust 20 percent revenue growth in preliminary Q1 results - Traders Union
CVRx Reports Strong Q1 Growth and Trial Progress - TipRanks
CVRx preliminary Q1 revenue rises 20%, gross margin improves - TradingView
CVRx (NASDAQ: CVRX) posts Q1 growth and advances BENEFIT-HF trial - Stock Titan
CVRx Reports Preliminary First Quarter 2026 Financial Results - marketscreener.com
CVRx says Medicare approval rates improved as heart device sales rose - Stock Titan
Forecast Cut: Is CVRX a speculative investmentCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
Bear Alert: Is CVRx Inc stock overvalued or fairly priced2026 Catalysts & Short-Term High Return Ideas - baoquankhu1.vn
CVRx, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
(CVRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Pharma News: Will CVRX benefit from government policyDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
Analysis Recap: Can CVRx Inc weather a recession2026 Price Action Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is CVRx (CVRX) Stock Stable Now | Price at $9.19, Up 2.00%Growth Investing - UBND thành phố Hải Phòng
CVRX Apr 2026 7.500 call (CVRX260417C00007500) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Apr 2026 10.000 put (CVRX260417P00010000) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):